Treatment of Alectinib in NSCLC with Brain Metastasis Patient Refractory to Radiotherapy after Resistance to Crizotinib: A Case Report and Literature Review

YUAN ZHOU
Tianjin Medical University  https://orcid.org/0000-0002-2215-6298

Xianliang Zeng
Tianjin Hospital

Songwei Sun
Tianjin Hospital

Xiuli Chen
Tianjin Hospital

Shuang Huang
Tianjin Hospital

Chunzi Zhang (zhchzh_6@hotmail.com)
Tianjin Hospital, Tianjin  https://orcid.org/0000-0002-9035-4990

Case report

Keywords: ALK, NSCLC, brain metastasis, radiotherapy, alectinib

DOI: https://doi.org/10.21203/rs.3.rs-342760/v2

License: © This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

**Background:** Brain metastasis is the common place of tumor recurrence after resistance to crizotinib. The therapeutic modes on brain metastasis of ALK-positive NSCLC require multidisciplinary approach, including target therapy, chemotherapy and radiotherapy. Until to nowadays, there isn’t optimal therapeutic recommendations for these patients. Radiotherapy is the vital treatment for brain metastasis.

**Case presentation:** We reported one ALK-positive NSCLC patient with brain metastasis after crizotinib. ALK rearrangement wasn’t found in blood sample of the patient by NGS. According to NCCN guideline, we gave the patient whole brain radiotherapy. It was unexpected that the number of brain metastasis increased after whole brain radiotherapy. After that, the patient was empirically used alectinib after radiotherapy failure. It achieved unexpected success in our patient.

**Conclusions:** We got some enlightenment form the patient. Firstly, liquid biopsy is complementary to tissue biopsy in NSCLC, mainly in EGFR mutation. However, ALK detection should use tissue biopsy as much as possible. Secondly, we suggest the brain metastasis patient of NSCLC use the second generation TKI, such as alectinib, ceritinib, after resistance to crizotinib whether ALKr is positive or negative in liquid biopsy. Lastly, we believe that combined radiotherapy with TKIs is an optimal mode in the BM patient of NSCLC after resistance to crizotinib.

**Background**

As a drive gene, anaplastic lymphoma kinase (ALK) gene rearrangement (ALKr) accounted for 2–7% of non-small-cell lung cancer (NSCLC) patients(Dagogojack et al., 2020). Therefore, targeting ALKr may precisely treat this subtype patients of NSCLC. As the first-generation drug of targeting ALKr, crizotinib have proved to efficaciously treat NSCLC patients harboring ALKr [2]. However, most patients go through tumor recurrence within 1 year after using crizotinib. Moreover, brain metastasis (BM), which remains a substantial cause of morbidity and mortality, is the common place of tumor recurrence[3]. The therapeutic modes on BM of ALK-positive NSCLC require multidisciplinary approach, including target therapy, chemotherapy and radiotherapy. Until to nowadays, there aren’t defined recommendations for these patients yet. Haihong et al reported that BM of ALK-positive lung adenocarcinoma patients had better overall survival by tyrosine-kinase inhibitors (TKIs) or cranial radiotherapy. Moreover, cranial radiotherapy still plays an important role in these patients[4]. Ineffective for radiotherapy hasn’t been previously reported in BM of ALK-positive lung adenocarcinoma patients. Herein, we reported that alectinib successfully treated one BM patient refractory to radiotherapy, which is ALK-negative in blood sample after resistance to crizotinib. In addition, we discuss the effect of different therapeutic modes in BM of ALK-positive lung adenocarcinoma by reviewing the relevant literature.

**Case Presentation**
A 67-year old man had smoked for more than 20 years, 20 cigarettes/day. He had quit smoking for 10 years. In July 2015, he was in Tianjin Medical University Cancer Institute and Hospital due to right supraclavicular lymph node enlargement. Physical examination found one right supraclavicular lymph node enlargement, which wasn\’t pain. Laboratory data revealed all normal except that carcinoembryonic antigen (CEA) is 8.7. PET revealed that one occupying lesion is in left lung. There is one right supraclavicular lymph node enlargement and multiple mediastinal lymphadenopathy. Moreover, there were multiple bone metastases, including the fourth cervical vertebra, the left first rib and the left pubis(Fig. 1a). According to the 8th edition of the classification of lung cancer, the stage of this patient is IV(T1cN3M1b). Transcutaneous needle biopsy was performed at the right supraclavicular lymph node enlargement. According to the immunohistochemical analysis, a diagnosis of poorly differentiated adenocarcinoma was made(Fig. 1b). By next-generation sequencing (NGS) and fluorescence in situ hybridization (FISH), ALK\(r\) was found in biopsy samples. So, the patient was started with crizotinib, and had a shrinkage in all lesions in three months after crizotinib. Laboratory data revealed CEA is 6.7. During the follow-up period, all lesions were further shrinkage except lesion of the left lung which was stable disease. Laboratory data revealed CEA is normal, that is under 5.0.

In October 2019, the patient was dizzy and pain in the right hip. PET revealed multiple bone metastases in the right ilium and the right ischium(Fig. 2a). Moreover, there were multiple metastatic focuses in the brain(Fig. 2a). Then, the contrasted MR showed that the number of BM is nine(Fig. 2b). Laboratory data revealed CEA is 3.6. We recommend a biopsy of the right iliac bone. Because the patient had symptoms of high intracranial pressure and deterioration of dizziness, the patient and his family members refused biopsy. ALK\(r\) wasnt found \(\in\) blood\(\text{samp}\) \(\leq\) ofthe\(\text{patientbyNGS}\). A or \(d \in g \rightarrow Liu\) report[5], the patient was given the whole brain radiation therapy (WBRT) combined with simultaneous integrated boost (SIB) which aimed at metastatic focuses. WBRT was delivered in a course of 39.6 Gy in 22 fractions. SIB was delivered in a course of 55 Gy in 22 fractions(Fig. 2c). The patient was given radiotherapy in the lesion of the right iliac bone as well. Radiotherapy was delivered in a course of 60 Gy in 24 fractions(Fig. 2d). With radiotherapy, the pain of the right hip was ebbing. However, the symptoms of high intracranial pressure took a turn for the worse. The patient underwent MR after finishing 10 fractions cranial radiotherapy. The MR showed that the number of brain metastasis increased to about 50(Fig. 3a). After careful consideration, we made decision to finish WBRT. After finishing WBRT, the patient developed into coma. MR showed that the number of BM increased to about 80(Fig. 3b). Some BM were in the brain stem. Faced with such a situation, we are desperate. WBRT is ineffective for this patient. What was the next therapy for this patient? Satoh Y et al reported that the overall concordance rate of ALK status was 100% according to immunostains between histologic and paired liquid-based cytology specimens[6]. However, Aldea M et al reported that the detection rate of genomic alterations is lower in the subset of isolated central nervous system progression patients[7]. The result of blood sample was doubtful. So, the patient received alectinib 600mg twice daily. After a week of oral alectinib, the consciousness of this patient gradually improved. After a month of oral alectinib, the patient`s physical symptoms gradually improved. MR showed that the number of brain metastasis decreased to about 60 and the total metastatic tumor volume decreased as well(Fig. 4a). Some metastatic focuses vanished,
especially in brain stem. It was pity that the right thalamus hemorrhaged and ruptured into ventricle in this patient because of stopping antihypertensive drugs autonomously. It was given to treat cerebral hemorrhage. Moreover, the patient continued to take alectinib. After a month of treatment in hemorrhage, the patient’s condition gradually stabilized. MR showed that most of the hematoma was absorbed and the number of brain metastasis further decreased to about 20(Fig. 4b). Furthermore, the total metastatic tumor volume further decreased as well.

**Discussion And Conclusion**

BM, which are a frequent complication in patients with NSCLC, is associated with poor survival outcomes and poses clinical challenges for oncologists[8]. At initial diagnosis, 10% of NSCLC patients have BM, and the brain is the only site of tumor relapse in 50% NSCLC patients[9]. However, in NSCLC patients harboring ALKr, the risk of BM is higher. The rate of BM is approximately 20% in NSCLC patients harboring ALKr at initial diagnosis and up to 75% in these patients by using crizotinib[10]. So, the therapeutic effect of BM plays an important role in prolonging overall survival and improving the quality of life. However, there isn’t a standard therapeutic mode in BM of NSCLC. A large number of studies have taken different strategies to treat BM of NSCLC, including surgery, radiotherapy, chemotherapy, targeted therapy, immunotherapy, and combination of different modes[11–15].

As well as this patient, radiotherapy plays an important role in treating BM of NSCLC harbouring driver-gene mutation, such as WBRT[13, 16, 17], stereotactic radiosurgery (SRS)[16–18], and so on. According to National Comprehensive Cancer Network (NCCN) recommendation, the patient was given the WBRT. In order to increase the local control, we used SIB to increase the dose of metastatic focuses. However, during the course of radiotherapy, it was unexpected that the number of the brain metastasis inexplicably increased in our case. The phenomenon has not been reported. The current studies mainly focus on that WBRT impairs cognitive function and quality of life and SRS is an alternative therapy for BM. Some studies showed that SRS obtained good local control and less cognitive deterioration in treating 1 to 3 brain metastases[19, 20]. Hughes RT et al reported that SRS alone adapted to treat these patients with 5 to 15 BM[21]. Recently, Robin TP et al found that BM patients with ALKr may be uniquely suited to benefit from SRS[20]. So, SRS alone may become a preferred strategy in treating brain metastases.

ALKr wasn’t found in blood sample of the patient by NGS. The patient continued using ALK inhibitor. If the patient was an ALK-positive in blood sample, the patient had combined radiotherapy with alectinib. Because of poor accumulation of crizotinib in CNS, many NSCLC patients with ALKr frequently experience BM after treatment with crizotinib. The second generation ALK inhibitor, that is alectinib, can retain a higher concentration in the CNS and enhance the efficacy in treating BM in NSCLC patients with ALKr[22]. After crizotinib failure for ALK-positive NSCLC patients, Novello S et al reported that alectinib significantly improved the efficacy of BM compared with chemotherapy[3]. Whether radiotherapy or TKIs or combined radiotherapy with TKIs can improved the efficacy of BM? By meta-analysis, Singh R et al reported that there was no significant difference between combined radiotherapy with TKIs compared with radiotherapy alone. Similarly, there was no significant difference in median overall survival among
TKIs alone, radiotherapy alone, and a combination of TKIs and radiotherapy[13]. So, the choice of three modes should be determined according to the specific situation of the patient. In our case, the patient was empirically used alectinib after radiotherapy failure. It achieved unexpected success in our patient.

In summary, we got some enlightenment from the patient. Firstly, liquid biopsy is complementary to tissue biopsy in NSCLC, mainly in EGFR mutation. However, ALK detection should use tissue biopsy as much as possible. Secondly, we suggest the BM patient of NSCLC use the second generation TKI, such as alectinib, ceritinib, after resistance to crizotinib whether ALKr is positive or negative in liquid biopsy. Lastly, we believe that combined radiotherapy with TKIs is an optimal mode in the BM patient of NSCLC after resistance to crizotinib.

**Abbreviations**

NSCLC: non-small-cell lung cancer; ALK: anaplastic lymphoma kinase; ALKr: anaplastic lymphoma kinase gene rearrangement; BM: brain metastasis; TKIs: tyrosine-kinase inhibitors; CEA: carcinoembryonic antigen; NGS: next-generation sequencing; FISH: fluorescence in situ hybridization; WBRT: whole brain radiation therapy; SIB: simultaneous integrated boost

**Declarations**

- **Ethics approval and consent to participate**

Not applicable; see the next item.

- **Consent for publication**

The consent form has been signed by the patient.

- **Availability of data and materials**

All the Patient's data and medical images can be found on the database of our Hospital.

- **Competing interests**

The author declare that they have no competing interest.

- **Funding**

None.

- **Authors' contributions**
Yuan Zhou carried out the literature search and drafted the article. Xianliang Zeng and Songwei Sun carried out image and data collection. Xiuli Chen and Shuang Huang collected important background information and performed image processing. Chunzhi Zhang made substantial contributions to the manuscript, including revising it critically for intellectual content. All authors read and approved the final manuscript.

- **Acknowledgements**

We acknowledge the work of colleagues in the Pathology and X-ray Department in offering the original images and data related to this article.

**References**

1. Dagogo-Jack I, Yoda S, Lennerz JK, Langenbucher A, Lin JJ, Rooney MM, Prutisto-Chang K, Oh A, Adams NA, Yeap BY et al: **MET Alterations Are a Recurring and Actionable Resistance Mechanism in ALK-Positive Lung Cancer.** *Clin Cancer Res* 2020, **26**(11):2535-2545.https://doi.org/10.1158/1078-0432.CCR-19-3906

2. Yang Y, Zhou J, Zhou J, Feng J, Zhuang W, Chen J, Zhao J, Zhong W, Zhao Y, Zhang Y et al: **Efficacy, safety, and biomarker analysis of ensartinib in crizotinib-resistant, ALK-positive non-small-cell lung cancer: a multicentre, phase 2 trial.** *Lancet Respir Med* 2020, **8**(1):45-53.https://doi.org/10.1016/S2213-2600(19)30252-8

3. Novello S, Mazieres J, Oh IJ, de Castro J, Migliorino MR, Helland A, Dziahdziszko R, Griesinger F, Kotb A, Zeaiter A et al: **Alectinib versus chemotherapy in crizotinib-pretreated anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer: results from the phase III ALUR study.** *Ann Oncol* 2018, **29**(6):1409-1416.https://doi.org/10.1093/annonc/mdy121

4. Yang H, He D, Wang F, Deng Q, Xie Z: **A study on different therapies and prognosis-related factors for brain metastases in lung adenocarcinoma patients with driver mutation.** *Clin Exp Metastasis* 2020, **37**(3):391-399.https://doi.org/10.1007/s10585-020-10026-2

5. Liu H, Xu X, Wang J, Wang W, Ma C, Sun T, Shao Q: **Clinical study on different doses and fractionated radiotherapies for multiple brain metastases of non-EGFR mutant lung adenocarcinoma.** *Ann Palliat Med* 2020.https://doi.org/10.21037/apm-20-1203

6. Satoh Y, Matsuo Y, Kuba T, Yamashita K, Sawano M, Tozaka S, Yamazaki H, Sonoda D, Mikubo M, Naito M et al: **EGFR mutation genotyping and ALK status determination in liquid-based cytology samples of non-small cell lung cancer.** *Virchows Arch* 2020, **476**(5):753-762.https://doi.org/10.1007/s00428-019-02692-9

7. Aldea M, Hendriks L, Mezquita L, Jovelet C, Planchard D, Auclin E, Remon J, Howarth K, Benitez JC, Gazzah A et al: **Circulating Tumor DNA Analysis for Patients with Oncogene-Addicted NSCLC With Isolated Central Nervous System Progression.** *J Thorac Oncol* 2020, **15**(3):383-391.https://doi.org/10.1016/j.jtho.2019.11.024
8. Boire A, Brastianos PK, Garzia L, Valiente M: **Brain metastasis.** *Nat Rev Cancer* 2020, 20(1):4-11.https://doi.org/10.1038/s41568-019-0220-y

9. Munsterberg J, Loreth D, Brylka L, Werner S, Karbanova J, Gandrass M, Schneegans S, Besler K, Hamester F, Robador JR et al: **ALCAM contributes to brain metastasis formation in non-small-cell lung cancer through interaction with the vascular endothelium.** *Neuro Oncol* 2020, 22(7):955-966.https://doi.org/10.1093/neuonc/noaa028

10. Itchins M, Lau B, Hudson AL, Westman H, Xia CY, Hayes SA, Howell VM, Rodriguez M, Cooper WA, Wei H et al: **ALK-Rearranged Non-Small Cell Lung Cancer in 2020: Real-World Triumphs in an Era of Multigeneration ALK-Inhibitor Sequencing Informed by Drug Resistance Profiling.** *Oncologist* 2020.https://doi.org/10.1634/theoncologist.2020-0075

11. Qing D, Zhao B, Zhou YC, Zhu HL, Ma DY: **Whole-brain radiotherapy plus sequential or simultaneous integrated boost for the treatment of a limited number of brain metastases in non-small cell lung cancer: A single-institution study.** *Cancer Med* 2020, 9(1):238-246.https://doi.org/10.1002/cam4.2696

12. Goldberg SB, Schalper KA, Gettinger SN, Mahajan A, Herbst RS, Chiang AC, Lilenbaum R, Wilson FH, Omay SB, Yu JB et al: **Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non-randomised, open-label, phase 2 trial.** *Lancet Oncol* 2020, 21(5):655-663.https://doi.org/10.1016/S1470-2045(20)30111-X

13. Singh R, Lehrer EJ, Ko S, Peterson J, Lou Y, Porter AB, Kotecha R, Brown PD, Zaorsky NG, Trifiletti DM: **Brain metastases from non-small cell lung cancer with EGFR or ALK mutations: A systematic review and meta-analysis of multidisciplinary approaches.** *Radiother Oncol* 2020, 144:165-179.https://doi.org/10.1016/j.radonc.2019.11.014

14. Lin JJ, Schoenfeld AJ, Zhu VW, Yeap BY, Chin E, Rooney M, Plodkowski AJ, Digumarthy SR, Dagogo-Jack I, Gainor JF et al: **Efficacy of Platinum/Pemetrexed Combination Chemotherapy in ALK-Positive NSCLC Refractory to Second-Generation ALK Inhibitors.** *J Thorac Oncol* 2020, 15(2):258-265.https://doi.org/10.1016/j.jtho.2019.10.014

15. Ramalingam SS, Vansteenkiste J, Planchard D, Cho BC, Gray JE, Ohe Y, Zhou C, Reungwetwattana T, Cheng Y, Chewaskulyong B et al: **Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC.** *N Engl J Med* 2020, 382(1):41-50.https://doi.org/10.1056/NEJMoa1913662

16. Chu L, Ni J, Yang X, Tong T, Wang J, Yin F, Li R, Li Y, Zou L, Li Y et al: **Radiographic Features of Metastatic Brain Tumors from ALK-rearranged Non-small Cell Lung Cancer: Implications for Optimal Treatment Modalities.** *J Cancer* 2019, 10(26):6660-6665.https://doi.org/10.7150/jca.30091

17. Arrieta Q, Ramirez-Tirado LA, Caballe-Perez E, Mejia-Perez A, Zatarain-Barron ZL, Cardona AF, Lozano-Ruiz F, Segura-Gonzalez M, Cruz-Rico G, Maldonado F et al: **Response rate of patients with baseline brain metastases from recently diagnosed non-small cell lung cancer receiving radiotherapy according to EGFR, ALK and KRAS mutation status.** *Thorac Cancer* 2020, 11(4):1026-1037.https://doi.org/10.1111/1759-7714.13359
18. Borghetti P, Bonu ML, Giubbolini R, Levra NG, Mazzola R, Perna M, Visani L, Meacci F, Taraborrelli M, Triggiani L et al: **Concomitant radiotherapy and TKI in metastatic EGFR- or ALK-mutated non-small cell lung cancer: a multicentric analysis on behalf of AIRO lung cancer study group.** *Radiol Med* 2019, **124**(7):662-670.https://doi.org/10.1007/s11547-019-00999-w

19. Brown PD, Jaeckle K, Ballman KV, Farace E, Cerhan JH, Anderson SK, Carrero XW, Barker FG, 2nd, Deming R, Burri SH et al: **Effect of Radiosurgery Alone vs Radiosurgery With Whole Brain Radiation Therapy on Cognitive Function in Patients With 1 to 3 Brain Metastases: A Randomized Clinical Trial.** *JAMA* 2016, **316**(4):401-409.https://doi.org/10.1001/jama.2016.9839

20. Robin TP, Camidge DR, Stuhr K, Nath SK, Breeze RE, Pacheco JM, Liu AK, Gaspar LE, Purcell WT, Doebele RC et al: **Excellent Outcomes with Radiosurgery for Multiple Brain Metastases in ALK and EGFR Driven Non-Small Cell Lung Cancer.** *J Thorac Oncol* 2018, **13**(5):715-720.https://doi.org/10.1016/j.jtho.2017.12.006

21. Hughes RT, McTyre ER, LeCompte M, Cramer CK, Munley MT, Laxton AW, Tatter SB, Ruiz J, Pasche B, Watabe K et al: **Clinical Outcomes of Upfront Stereotactic Radiosurgery Alone for Patients With 5 to 15 Brain Metastases.** *Neurosurgery* 2019, **85**(2):257-263.https://doi.org/10.1093/neuros/nyy276

22. Yang YL, Xiang ZJ, Yang JH, Wang WJ, Xiang RL: **Effect of alectinib versus crizotinib on progression-free survival, central nervous system efficacy and adverse events in ALK-positive non-small cell lung cancer: a systematic review and meta-analysis.** *Ann Palliat Med* 2020.https://doi.org/10.21037/apm-19-643

**Figures**
A T1cN3M1b NSCLC patient. (a). PET revealed that one occupying lesion is in left lung. There is one right supraclavicular lymph node enlargement and multiple mediastinal lymphadenopathy. Moreover, there were multiple bone metastases, including the fourth cervical vertebra, the left first rib and the left pubis. (b). According to the immunohistochemical analysis, a diagnosis of poorly differentiated adenocarcinoma was made.
Figure 2

Tumor recurrence after treatment of crizotinib. (a). PET revealed multiple bone metastases in the right ilium and the right ischium. Moreover, there were multiple metastatic focuses in the brain. (b). The contrasted MR showed that the patient had BM. (c). The dose distribution of radiotherapy in BM. (d). The dose distribution of radiotherapy in the lesion of the right iliac bone.
The number of BM increased after radiotherapy. (a). The MR showed that the number of brain metastasis increased to about 50. (b). MR showed that the number of BM increased to about 80.
Figure 4

The number of BM decreased after treatment of alectinib. (a). MR showed that the number of brain metastasis decreased to about 60. (b). The number of brain metastasis further decreased to about 20.